The Outcomes of Convalescent Plasma Therapy in Severe COVID-19 Patients Compared with Standard of Care; a Case-control Study
Completed
- Conditions
- Coronavirus disease 2019 (COVID-19) causes severe pneumonia, respiratory failure, and high mortality. The COVID-19 convalescent plasma therapy (CPT) with a high titer of neutralizing antibodies is needed to prove the benefit in reducing mortality.COVID-19, convalescent plasma, severe COVID-19, Mortality
- Registration Number
- TCTR20220101003
- Lead Sponsor
- Center of Learning and Research in Celebration of HRH Princess Chulabhorn 60th Birthday Anniversary
- Brief Summary
The CPT study demonstrated lower mortality (15%) in the CPT arm with a low hazard ratio in Cox-regression univariate and multivariate analysis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 107
Inclusion Criteria
107 cases compatible with severe COVID-19 definition
Exclusion Criteria
Excluded 1,261 of mild cases
-Excluded 1,260 of moderate cases
-Exclude 40 of severe cases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method CPT study could decrease mortality rate 85% 14-days mortality questionnaire
- Secondary Outcome Measures
Name Time Method The WHO clinical progression scale WHO clinical progression scale on day 0,3,5,14, after admission questionnaire